Stalevo (Carbidopa / Levodopa / Entacapone) - Summary

STALEVO SUMMARY

Stalevo® (carbidopa, levodopa and entacapone) is a combination of carbidopa, levodopa and entacapone for the treatment of Parkinson's disease.

Stalevo® (carbidopa, levodopa and entacapone) is indicated to treat patients with idiopathic Parkinson's disease:

1. To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered asindividual products.
2. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION).

STALEVO NEWS HIGHLIGHTS

Media Articles Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Parkinson's Disease
Source: MedicineNet levodopa-carbidopa Specialty [2005.12.17]

Transdermal Rotigotine Patch Safe, Effective in Early Idiopathic Parkinson's Disease
Source: Medscape Pharmacotherapy Headlines [2004.06.17]

Using Plastic Coatings To Help Medical Implants Connect With Neurons
Source: Eye Health / Blindness News From Medical News Today [2008.08.22]

Scientists Replicate Diseases In The Lab With New Stem Cell Lines
Source: Muscular Dystrophy / ALS News From Medical News Today [2008.08.08]

more>>

Published Studies Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. [2007.11]

Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]

Should levodopa dose be reduced when switched to stalevo? [2008.03]

[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life] [2008.01.30]

Entacapone Prolongs the Reduction of PLM by Levodopa/Carbidopa in Restless Legs Syndrome. [2007]

more>>

Clinical Trials Related to Stalevo (Carbidopa / Levodopa / Entacapone)

Study to Evaluate Initiation of Stalevo in Early Wearing-Off [Completed]

Stalevo in Early Wearing-Off Patients [Active, not recruiting]

PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding [Terminated]

Pharmacokinetic Study With Repeated Doses of Stalevo [Completed]

Adherence of Stalevo, Entacapone and Levodopa [Completed]

more>>